3- carbamyl- (3'- picolyl)- 4- methoxy- 1- benzamide

a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist; used as a protective agent in splanchnic artery occlusion shock

Also Known As:

G 619; G-619; 1,3-Benzenedicarboxamide, 4-methoxy-N3-(3-pyridinylmethyl)-

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bathri, Rashmi: 1 article (07/2019)
2.	Chatterjee, Nirupama: 1 article (07/2019)
3.	Shrivastava, Manisha: 1 article (07/2019)

Related Diseases

1.	Shock 01/01/1992 - "These data further confirm the involvement of TxA2 in SAO shock and suggest that G 619 may have positive effects in low-flow states." 01/01/1992 - "Finally, the administration of G 619 had beneficial effects on changes in MAP-induced bay SAO shock. " 01/01/1992 - "Protective effects of G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, in splanchnic artery occlusion shock." 01/01/1992 - "The administration of G 619, a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist (50 mg/kg, 15 min before SAO shock) significantly increased survival time (190 +/- 13 min) and survival rate, reduced plasma levels of TxB2, and partially restored the impairment in peritoneal macrophage phagocytosis. "
2.	beta-Thalassemia (Cooley's Anemia) 07/01/2019 - "PCR was performed for rare Hb disorders such as Hb Lepore and δ β chain disorder by GAP PCR in addition to five common Indian beta-thalassemia mutations IVS1-5 (G-C), IVS1-1 (G-T), Cd41/42 (-TCTT), Cd8/9 (+G), 619 bp deletion. "
3.	Necrosis 09/01/1993 - "The administration of G 619 significantly increased survival rate, lowered the area of necrosis, blunted the increase in serum CPK activity and reduced the increase in MPO activity in both the area at risk and the necrotic area. "
4.	Myocardial Infarction 09/01/1993 - "These data are consistent with an involvement of TxA2 in MI/R injury and suggest that G 619 may represent a novel therapeutic approach to the treatment of acute myocardial infarction."
5.	Hypotension (Low Blood Pressure) 11/03/1995 - "Pretreatment with G 619 in vivo significantly protected against Salmonella enteritidis lipopolysaccharide-induced lethality (80% survival rate and 60% survival rate 24 h and 72 h after Salmonella enteritidis lipopolysaccharide injection, respectively), reduced hypotension, decreased plasma thromboxane B2 and serum tumor necrosis factor-alpha levels and enhanced blood levels of 6-keto-prostaglandin F1 alpha. "

Related Drugs and Biologics

1.	Prostaglandin H2 Thromboxane A2 Receptors
2.	Thromboxanes
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
4.	Thromboxane B2
5.	Lipopolysaccharides
6.	hemoglobin Lepore